Abstract
Peng Cao, Yanfang Chen
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Benign prostatic hyperplasia - what do we know?
10.1111/bju.15229 · 2021
Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019.
2021
Benign prostatic hyperplasia: rapid evidence review.
2023
Association between metabolic syndrome and benign prostatic hyperplasia: the underlying molecular connection.
10.1016/j.lfs.2024.123192 · 2024
National prevalence and incidence of benign prostatic hyperplasia/lower urinary tract symptoms and validated risk factors pattern.
10.1080/13685538.2025.2478875 · 2025
Causal associations between lifestyle habits and risk of benign prostatic hyperplasia: a two-sample Mendelian Randomization Study.
10.1093/gerona/glad187 · 2024
The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis.
10.1177/15579883261436335 · 2026
Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.
10.1177/20420188211066210 · 2021
Is uric acid a true antioxidant? Identification of uric acid oxidation products and their biological effects.
10.1080/13510002.2025.2498105 · 2025
Hyperuricemia and its related diseases: mechanisms and advances in therapy.
10.1038/s41392-024-01916-y · 2024
Uric acid in inflammation and the pathogenesis of atherosclerosis.
10.3390/ijms222212394 · 2021
Uric acid in metabolic syndrome: does uric acid have a definitive role?
10.1016/j.ejim.2022.04.022 · 2022
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
10.1016/j.redox.2022.102271 · 2022
Hypouricemia and mortality risk in the US general population.
10.1002/acr.24476 · 2021
Association between metabolic syndrome and uric acid: a systematic review and meta-analysis.
10.1038/s41598-022-22025-2 · 2022
New markers in metabolic syndrome.
10.1016/bs.acc.2022.06.002 · 2022
Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions.
10.1016/j.intimp.2024.111932 · 2024
Increased risk of benign prostate hyperplasia (BPH) in patients with gout: a longitudinal follow-up study using a National Health Screening Cohort.
10.3390/diagnostics14010055 · 2023
Is there relationship between serum uric acid levels and lower urinary tract symptoms, prostate volume, and PSA in men without cancer? A prospective population-based study.
10.1111/and.14200 · 2021
Association of serum uric acid levels with benign prostatic hyperplasia in US men: results from NHANES 2005-2008.
10.1080/13685538.2023.2275775 · 2023
Higher levels of serum uric acid have a significant association with lower incidence of lower urinary tract symptoms in healthy Korean men.
10.3390/metabo12070649 · 2022
Urate transport in health and disease.
10.1016/j.berh.2021.101717 · 2021
Uric acid in health and disease: from physiological functions to pathogenic mechanisms.
10.1016/j.pharmthera.2024.108615 · 2024
Nowcasting and forecasting the care needs of the older population in China: analysis of data from the China Health and Retirement Longitudinal Study (CHARLS).
10.1016/s2468-2667(22)00203-1 · 2022
Association between elevated serum uric acid levels and high estimated glomerular filtration rate with reduced risk of low muscle strength in older people: a retrospective cohort study.
10.1186/s12877-023-04374-3 · 2023
The rising worldwide impact of benign prostatic hyperplasia.
10.1111/bju.15286 · 2021
The etiology and pathogenesis of benign prostatic hyperplasia: the roles of sex hormones and anatomy.
2024
Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options.
10.1111/iju.15518 · 2024
Risk factors for benign prostatic hyperplasia: a comprehensive review.
10.1590/1806-9282.20250343 · 2025
Cross-sectional study on the association between serum uric acid levels and the risk of benign prostatic hyperplasia.
10.1136/bmjopen-2024-092844 · 2025
Probenecid and eugenol mitigate testosterone induced benign prostatic hyperplasia by targeting uric acid-induced inflammation and pro-survival pathways.
10.1002/pros.70026 · 2025
Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011-2016.
10.21037/tau-20-1114 · 2021
Establishment of sex difference in circulating uric acid is associated with higher testosterone and lower sex hormone-binding globulin in adolescent boys.
10.1038/s41598-021-96959-4 · 2021
Intrinsic and extrinsic factors causing hyperplasia of the prostate.
10.1111/iju.15446 · 2024
Serum uric acid to high-density lipoprotein ratio as a novel indicator of inflammation is correlated with the presence and severity of metabolic syndrome: a large-scale study.
10.1002/edm2.446 · 2023
Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging.
10.3389/fimmu.2022.842008 · 2022
The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer.
10.3390/cancers15123110 · 2023
Benign prostatic hyperplasia - a novel autoimmune disease with a potential therapy consequence?
10.1016/j.autrev.2023.103511 · 2024
The modulatory effects of cinnamaldehyde on uric acid level and IL-6/JAK1/STAT3 signaling as a promising therapeutic strategy against benign prostatic hyperplasia.
10.1016/j.taap.2020.115122 · 2020
Correlation between testosterone replacement treatment and lower urinary tract symptoms.
10.5213/inj.2040234.117 · 2021
Exercise and physical activity as modifiable risk factors for benign prostatic hyperplasia: an update.
10.1007/s11934-026-01346-z · doi-reference
Food ultra-processing, plant-origin foods, and risk of benign prostatic hyperplasia: evidence from the UK Biobank cohort.
10.1186/s12937-026-01310-0 · doi-reference
Urban-rural differences in self-reported physician-diagnosed BPH and associated factors among older men: a cross-sectional analysis of a national survey.
10.1177/00469580261422684 · doi-reference
Elevated estradiol and DHT levels in the prostatic stroma as key drivers of benign prostatic hyperplasia pathogenesis.
10.3390/ijms27156785 · doi-reference
Correlation between testosterone replacement treatment and lower urinary tract symptoms.
10.5213/inj.2040234.117 · doi-reference
The modulatory effects of cinnamaldehyde on uric acid level and IL-6/JAK1/STAT3 signaling as a promising therapeutic strategy against benign prostatic hyperplasia.
10.1016/j.taap.2020.115122 · doi-reference
Benign prostatic hyperplasia - a novel autoimmune disease with a potential therapy consequence?
10.1016/j.autrev.2023.103511 · doi-reference
The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer.
10.3390/cancers15123110 · doi-reference
Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging.
10.3389/fimmu.2022.842008 · doi-reference
Serum uric acid to high-density lipoprotein ratio as a novel indicator of inflammation is correlated with the presence and severity of metabolic syndrome: a large-scale study.
10.1002/edm2.446 · doi-reference
Intrinsic and extrinsic factors causing hyperplasia of the prostate.
10.1111/iju.15446 · doi-reference
Establishment of sex difference in circulating uric acid is associated with higher testosterone and lower sex hormone-binding globulin in adolescent boys.
10.1038/s41598-021-96959-4 · doi-reference
Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011-2016.
10.21037/tau-20-1114 · doi-reference
Probenecid and eugenol mitigate testosterone induced benign prostatic hyperplasia by targeting uric acid-induced inflammation and pro-survival pathways.
10.1002/pros.70026 · doi-reference
Cross-sectional study on the association between serum uric acid levels and the risk of benign prostatic hyperplasia.
10.1136/bmjopen-2024-092844 · doi-reference
Risk factors for benign prostatic hyperplasia: a comprehensive review.
10.1590/1806-9282.20250343 · doi-reference
Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options.
10.1111/iju.15518 · doi-reference
The rising worldwide impact of benign prostatic hyperplasia.
10.1111/bju.15286 · doi-reference
Association between elevated serum uric acid levels and high estimated glomerular filtration rate with reduced risk of low muscle strength in older people: a retrospective cohort study.
10.1186/s12877-023-04374-3 · doi-reference
Nowcasting and forecasting the care needs of the older population in China: analysis of data from the China Health and Retirement Longitudinal Study (CHARLS).
10.1016/s2468-2667(22)00203-1 · doi-reference
Uric acid in health and disease: from physiological functions to pathogenic mechanisms.
10.1016/j.pharmthera.2024.108615 · doi-reference
Urate transport in health and disease.
10.1016/j.berh.2021.101717 · doi-reference
Higher levels of serum uric acid have a significant association with lower incidence of lower urinary tract symptoms in healthy Korean men.
10.3390/metabo12070649 · doi-reference
Association of serum uric acid levels with benign prostatic hyperplasia in US men: results from NHANES 2005-2008.
10.1080/13685538.2023.2275775 · doi-reference
Is there relationship between serum uric acid levels and lower urinary tract symptoms, prostate volume, and PSA in men without cancer? A prospective population-based study.
10.1111/and.14200 · doi-reference
Increased risk of benign prostate hyperplasia (BPH) in patients with gout: a longitudinal follow-up study using a National Health Screening Cohort.
10.3390/diagnostics14010055 · doi-reference
Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions.
10.1016/j.intimp.2024.111932 · doi-reference
New markers in metabolic syndrome.
10.1016/bs.acc.2022.06.002 · doi-reference
Association between metabolic syndrome and uric acid: a systematic review and meta-analysis.
10.1038/s41598-022-22025-2 · doi-reference
Hypouricemia and mortality risk in the US general population.
10.1002/acr.24476 · doi-reference
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
10.1016/j.redox.2022.102271 · doi-reference
Uric acid in metabolic syndrome: does uric acid have a definitive role?
10.1016/j.ejim.2022.04.022 · doi-reference
Uric acid in inflammation and the pathogenesis of atherosclerosis.
10.3390/ijms222212394 · doi-reference
Hyperuricemia and its related diseases: mechanisms and advances in therapy.
10.1038/s41392-024-01916-y · doi-reference
Is uric acid a true antioxidant? Identification of uric acid oxidation products and their biological effects.
10.1080/13510002.2025.2498105 · doi-reference
Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.
10.1177/20420188211066210 · doi-reference
The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis.
10.1177/15579883261436335 · doi-reference
Causal associations between lifestyle habits and risk of benign prostatic hyperplasia: a two-sample Mendelian Randomization Study.
10.1093/gerona/glad187 · doi-reference
National prevalence and incidence of benign prostatic hyperplasia/lower urinary tract symptoms and validated risk factors pattern.
10.1080/13685538.2025.2478875 · doi-reference
Association between metabolic syndrome and benign prostatic hyperplasia: the underlying molecular connection.
10.1016/j.lfs.2024.123192 · doi-reference